|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | |
| A61K 31/4439 | |||
| A61P 35/00 | |||
| A61K 39/395 |
| (11) | Number of the document | 3102605 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15703439.8 |
| Date of filing the European patent application | 2015-02-03 | |
| (97) | Date of publication of the European application | 2016-12-14 |
| (45) | Date of publication and mention of the grant of the patent | 2018-11-14 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/014212 |
| Date | 2015-02-03 |
| (87) | Number | WO 2015/119930 |
| Date | 2015-08-13 |
| (30) | Number | Date | Country code |
| 201461935809 P | 2014-02-04 | US |
| (72) |
MARTINI, Jean-francois, Andre, US
TARAZI, Jamal, Christo, US
PERINI, Rodolfo, Fleury, US
MAURO, David, J., US
|
| (73) |
Pfizer Inc.,
235 East 42nd Street, New York, NY 10017,
US
Merck Sharp & Dohme Corp., 126 East Lincoln Avenue, Rahway, NJ 07065, US |
| (54) | COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER |
| COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER |